GLP-1 receptor agonists have established compelling evidence for the commercial value of multi-indication drug development beyond obesity. Conventional paradigms for drug development must shift in order to adapt to multi...
Press releases
-
ICON wins industry accolades from TIME Magazine, Forbes and Financial Times in second half of 2023
ICON plc finishes the second half of 2023 with positive recognition as a top-rated employer and leader in clinical trial innovation.
-
ICON secures upgraded credit rating from Moody’s Investors Service
Moody's Investors Service ("Moody's") upgraded all of ICON plc’s instrument ratings to Baa3 with a stable outlook. This reflects the stronger credit profile of the ICON Group, which Moody’s now views as comparable in aggregate to Baa3 peers.
-
ICON reports third quarter 2023 results
Quarter three revenue of $2,055.1 million representing an increase of 5.8% on prior year revenue.
-
ICON secures upgraded credit rating from S&P Global Ratings
ICON plc today announced that S&P Global Ratings (S&P) upgraded ICON to an investment grade credit rating of BBB- with a stable outlook, based on operating performance and deleveraging.
-
ICON schedules third quarter 2023 earnings conference call
ICON plc announced that it will release its financial results for the third quarter 2023 after the market closes on Wednesday, October 25, 2023.
-
ICON releases expanded end-to-end Clinical Trial Tokenisation solution
ICON announces the release of its next generation Clinical Trial Tokenisation solution.
-
BARDA partners with ICON to execute next generation COVID-19 vaccines clinical trial
ICON plc today announces that it is partnering with BARDA to execute a clinical trial to evaluate the effectiveness of next generation COVID-19 vaccine candidates.
-
ICON shareholders vote in favour of all resolutions at its Annual General Meeting
All resolutions at the Annual General Meeting of the Company (AGM) held on July 25, 2023 were all duly passed by shareholders.
-
ICON reports second quarter 2023 results
Net business wins in the quarter of $2,419 million; a net book to bill of 1.20 or 1.21 on a trailing twelve month basis.
-
ICON recognised for CRO excellence
Industry awards as an employer of choice and for its creative and digital services.
